Who
Alfonso Quintas Cardama
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Foghorn Therapeutics; Chief Medical Officer, Tcr2 Therapeutics.
In numbers
- Trades disclosed
- 52
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $40K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Apr 2019
- Last trade
- 30 Jan 2026
- Last filed
- 2 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 2 Feb 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.7M300,000 at $5.71 | filing |
| 30 Jan 2026filed 2 Feb 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.7M300,000 at $5.71 | filing |
| 22 Jan 2025filed 24 Jan 2025 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $546K125,000 at $4.37 | filing |
| 24 Jan 2024filed 25 Jan 2024 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $184K60,000 at $3.06 | filing |
| 11 Sep 2023filed 13 Sep 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.1M272,000 at $7.57 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —70,649 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —31,582 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,346 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —90,720 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —114,700 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,775 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,409 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —6,489 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,549 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeutics | SEC FORM 4 Code D | —109,459 | filing |
| 15 Dec 2022filed 19 Dec 2022 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code A | —70,649 at $0.00 | filing |
| 15 Dec 2022filed 19 Dec 2022 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,775 at $0.00 | filing |
| 13 Dec 2022filed 13 Dec 2022 | Tcr2 Therapeutics | SEC FORM 4 Sold | $5,0374,752 at $1.06 | filing |
| 12 Dec 2022filed 13 Dec 2022 | Tcr2 Therapeutics | SEC FORM 4 Sold | $5,0454,586 at $1.10 | filing |
| 9 Dec 2022filed 13 Dec 2022 | Tcr2 Therapeutics | SEC FORM 4 Sold | $5,0414,461 at $1.13 | filing |
News
No headline names them, or the companies they trade most, lately.